A controversial new sporting venture is challenging one of the most fundamental principles of modern athletics — the ban on performance-enhancing drugs.
The International Fund for Agricultural Development (IFAD) has joined the World Bank Group's Water Forward, a new global initiative that aims to deliver water security for up to 1 billion people by 2030.
Thumbay University Hospital has inaugurated its Institute of Neurosciences, a dedicated centre for the diagnosis, treatment, and management of complex disorders of the brain, spine, and nervous system.
Johnson & Johnson has announced a new initiative in the United Arab Emirates aimed at supporting access to liquid biopsy testing for patients diagnosed with metastatic non-small cell lung cancer (NSCLC).
CE-Ventures, the corporate venture capital arm of Crescent Enterprises, on Tuesday announced that its portfolio company CrossBridge Bio has entered into a definitive agreement to be acquired by US pharmaceutical major Eli Lilly and Company.
Qiddiya Investment Company has signed an agreement with King Faisal Specialist Hospital and Research Centre (KFSH) for joint collaboration on the establishment of a premium facility in Riyadh that will deliver specialised sports medicine services in line with international standards.
The Women's Pavilion at Expo City Dubai, in partnership with Meem Foundation, American Hospital Dubai and PeriCare, has launched Her Health Majlis – an ongoing wellness series offering accessible, stigma-free education on women's health.
Researchers at NYU Abu Dhabi have developed smart molecules capable of both detecting and treating cancer, offering a safer and more precise approach to care. Farah Benyettou, lead researcher, and Thirumurugan Prakasam, a research scientist, were part of the team.
The installed renewable energy capacity has exceeded 7.7 gigawatts (GW), with projects under development expected to raise total capacity to more than 23 GW by 2031, a WAM news agency report said.
Emirates Drug Establishment (EDE) has approved Foundayo (orforglipron), an innovative oral treatment for chronic weight management, making the UAE the second country in the world to register the medication, developed by global pharmaceutical company Eli Lilly.
